Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Res Exp Med (Berl) ; 195(2): 85-92, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-7659838

RESUMO

Major surgical trauma has been considered as a cause of immunosuppression mainly through the production of prostaglandin E2 from activated monocytes/macrophages. In the present study we investigated the effect of parenteral indomethacin--a cyclo-oxygenase inhibitor--on T-lymphocyte subsets and cytokine production in patients under major operations. We studied 20 patients undergoing major surgical procedures, 10 of whom were randomly treated pre- and post-operatively with indomethacin (group 2) and 10 were not (group 2). We measured total T-cells, T-helper, T-suppressor, T-helper/T-suppressor (Th/Ts) cell ratio, NK-cells and interleukin (IL-1) and tumor necrosis factor production by endotoxin- or phytohemagglutinin-stimulated peripheral blood mononuclear cells, before operation and at days 1, 3 and 7 postoperatively. We detected a significant increase in Th/Ts cell ratio and an improvement in delayed type hypersensitivity response in the treated group at day 3. We believe that the above immunomodulating effect of in vivo cyclo-oxygenase inhibition may be beneficial in patients under major surgical procedures with a high susceptibility to postoperative infections.


Assuntos
Citocinas/biossíntese , Hipersensibilidade Tardia/imunologia , Indometacina/farmacologia , Neoplasias/cirurgia , Subpopulações de Linfócitos T/efeitos dos fármacos , Adulto , Idoso , Feminino , Humanos , Indometacina/administração & dosagem , Injeções Intramusculares , Interleucina-1/biossíntese , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/metabolismo , Ativação Linfocitária/imunologia , Contagem de Linfócitos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Neoplasias/imunologia , Subpopulações de Linfócitos T/imunologia , Fator de Necrose Tumoral alfa/biossíntese
2.
Cancer ; 82(2): 395-402, 1998 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-9445198

RESUMO

BACKGROUND: The aim of the current prospective, randomized control study was to investigate the effect of dietary omega-3 polyunsaturated fatty acids plus vitamin E on the immune status and survival of well-nourished and malnourished patients with generalized malignancy. METHODS: Sixty patients with generalized solid tumors were randomized to receive dietary supplementation with either fish oil (18 g of omega-3 polyunsaturated fatty acids, PUFA) or placebo daily until death. Each group included 15 well-nourished and 15 malnourished patients. The authors measured total T cells, T-helper cells, T-suppressor cells, natural killer cells, and the synthesis of interleukin-1, interleukin-6, and tumor necrosis factor by peripheral blood mononuclear cells before and on Day 40 of fish oil supplementation. Karnofsky performance status, nutritional state, and survival were also estimated. RESULTS: The ratio of T-helper cells to T-suppressor cells was significantly lower in malnourished patients. Omega-3 PUFA had a considerable immunomodulating effect by increasing this ratio in the subgroup of malnourished patients. There were no significant differences in cytokine production among the various groups, except for a decrease in tumor necrosis factor production in malnourished cancer patients, which was restored by omega-3 fatty acids. The mean survival was significantly higher for the subgroup of well-nourished patients in both groups, whereas omega-3 fatty acids prolonged the survival of all the patients. CONCLUSIONS: Malnutrition appears to be an important predictor of survival for patients with end stage malignant disease. Omega-3 polyunsaturated fatty acids had a significant immunomodulating effect and seemed to prolong the survival of malnourished patients with generalized malignancy.


Assuntos
Estado Terminal , Suplementos Nutricionais , Ácidos Graxos Ômega-3/uso terapêutico , Hospedeiro Imunocomprometido , Neoplasias/fisiopatologia , Vitamina E/uso terapêutico , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/uso terapêutico , Estado Terminal/terapia , Ácidos Graxos Ômega-3/administração & dosagem , Feminino , Seguimentos , Humanos , Hospedeiro Imunocomprometido/efeitos dos fármacos , Interleucina-1/sangue , Interleucina-6/sangue , Avaliação de Estado de Karnofsky , Células Matadoras Naturais/efeitos dos fármacos , Células Matadoras Naturais/patologia , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/metabolismo , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Neoplasias/complicações , Distúrbios Nutricionais/dietoterapia , Distúrbios Nutricionais/tratamento farmacológico , Distúrbios Nutricionais/etiologia , Estado Nutricional , Placebos , Estudos Prospectivos , Taxa de Sobrevida , Linfócitos T/efeitos dos fármacos , Linfócitos T/patologia , Linfócitos T Auxiliares-Indutores/efeitos dos fármacos , Linfócitos T Auxiliares-Indutores/patologia , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/patologia , Fator de Necrose Tumoral alfa/metabolismo , Vitamina E/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA